News

18 Dec 2012
Cellectis: an innovative anti-cancer approach. The University College of London and Cellectis have signed a collaboration agreement to develop a T-cell adoptive immunotherapy to fight leukemia
Cellectis (Alternext: ALCLS), the genome engineering specialist, announces today the signing of a broad collaboration agreement with the University College of London (UCL) on the...
Copyright 2012 Cellectis
Design & Development by EtonDigital